Clinical Questions in Cardiology: Using Glucagon-like Peptide-1 Receptor Agonists

Annenberg Center for Health Sciences
  • 0.0 (0)
  • MEDICINE

In this activity, case studies commonly encountered in cardiology practice are utilized to prompt reflection on opportunities for reducing cardiovascular risk. Drawing on seminal research and their own experience, cardiologist Jorge Plutzy, MD, and endocrinologist Helena Rodbard, MD, navigate through a series of ‘clinical questions’ to inform regarding the clinical pharmacology of the GLP-1RAs and their evidence-based role in cardiovascular risk reduction, particularly in patients with secondary atherosclerotic cardiovascular disease.

Episodes

  1. 03/05/2024

    Cardiologist Collaboration

    Role in Diabetes Management Multidisciplinary Team-based Approach

    5 min

  2. 03/05/2024

    Individualizing Therapy

    Drug Initiation and Monitoring Contraindications and Adverse Effects Patient Education

    8 min

  3. 03/05/2024

    Cardiovascular Benefits

    FDA Indications Clinical Trial Evidence

    4 min

  4. 03/05/2024

    Glycemic/Non-Glycemic Effects

    Short-Acting versus Long-Acting Agents Fasting and Postprandial Blood Glucose Gastric Emptying and Body Weight

    5 min

  5. 03/05/2024

    Pathophysiologic Targets

    Diabetes Pathophysiology Glucagon-Like Peptide-1 Mechanisms

    5 min

  6. 03/05/2024

    Guideline Recommendations

    Diabetes Guidelines Chronic Coronary Disease Guidelines

    13 min

  7. 03/05/2024

    Introduction and Case Vignettes

    Meet Jorge Plutzky, MD and Helena Rodbard, MD. This episode covers: Faculty Introduction Case Vignettes Cardiovascular Risk Reduction

    12 min
  • 7 Episodes

About

In this activity, case studies commonly encountered in cardiology practice are utilized to prompt reflection on opportunities for reducing cardiovascular risk. Drawing on seminal research and their own experience, cardiologist Jorge Plutzy, MD, and endocrinologist Helena Rodbard, MD, navigate through a series of ‘clinical questions’ to inform regarding the clinical pharmacology of the GLP-1RAs and their evidence-based role in cardiovascular risk reduction, particularly in patients with secondary atherosclerotic cardiovascular disease.

Information